Pharmafile Logo

Synpromics

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Edinburgh, UK - September 20th, 2017 - Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for...

Synpromics expands facilities to meet demand for revolutionary gene control technology

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based...

Synpromics announces a research collaboration with GE Healthcare to extend the toolbox for production of biologics

Edinburgh, UK, 4th January 2017 - Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcareís proprietary biopharmaceutical manufacturing platform.
https://www.synpromics.com
info@synpromics.com
Roslin Innovation Centre, Easter Bush Campus, Midlothian, EH25 9RG

+44 (0) 131 651 9662